Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

April 30, 2027

Conditions
Interstitial Lung DiseaseSurfactant Dysfunction
Interventions
DRUG

Hydroxychloroquine

Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug. hydroxychloroquine has been reported to improve the clinical status of chILD cases wtih genetic causes. The exact mechanism of action of hydroxychloroquine is unknown. In additon to having anti-inflammatory properties, hydroxychloroquine has been shown to affect intracellular processing of surfactant protein.

Trial Locations (1)

201102

RECRUITING

Children's hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Children's Hospital of Fudan University

OTHER